Chang HM - Search Results

1

Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group trial.

Kim TW, Kang WK, Chang HM, Park JO, Ryoo BY, Ahn JS, Zang DY, Lee KH, Kang YK, Kim SR, Kim HK; Korean Cancer Study Group. Kim TW, et al. Among authors: chang hm. Acta Oncol. 2005;44(3):230-5. doi: 10.1080/02841860510029590. Acta Oncol. 2005. PMID: 16076694 Clinical Trial.

2

Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer.

Ahn JH, Kang YK, Kim TW, Bahng H, Chang HM, Kang WC, Kim WK, Lee JS, Park JS. Ahn JH, et al. Among authors: chang hm. Cancer Chemother Pharmacol. 2002 Aug;50(2):104-10. doi: 10.1007/s00280-002-0483-x. Epub 2002 Jun 25. Cancer Chemother Pharmacol. 2002. PMID: 12172973 Clinical Trial.

3

Locally advanced acinar cell carcinoma of the pancreas successfully treated by capecitabine and concurrent radiotherapy: report of two cases.

Lee JL, Kim TW, Chang HM, Lee SK, Kim MH, Kang YK, Kim JS, Kim JH. Lee JL, et al. Among authors: chang hm. Pancreas. 2003 Jul;27(1):e18-22. doi: 10.1097/00006676-200307000-00019. Pancreas. 2003. PMID: 12826914 No abstract available.

4

Phase II study of gemcitabine, UFT and leucovorin in patients with advanced pancreatic cancer.

Kim TW, Kang HJ, Ahn JH, Lee K, Chang HM, Kang YK, Lee JS. Kim TW, et al. Among authors: chang hm. Acta Oncol. 2002;41(7-8):689-94. doi: 10.1080/028418602321028328. Acta Oncol. 2002. PMID: 14651215 Clinical Trial.

5

Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors.

Kim TW, Lee H, Kang YK, Choe MS, Ryu MH, Chang HM, Kim JS, Yook JH, Kim BS, Lee JS. Kim TW, et al. Among authors: chang hm. Clin Cancer Res. 2004 May 1;10(9):3076-81. doi: 10.1158/1078-0432.ccr-03-0581. Clin Cancer Res. 2004. PMID: 15131046

6

Hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy.

Heo YS, Chang HM, Kim TW, Ryu MH, Ahn JH, Kim SB, Lee JS, Kim WK, Cho HK, Kang YK. Heo YS, et al. Among authors: chang hm. J Clin Pharmacol. 2004 Oct;44(10):1166-72. doi: 10.1177/0091270004268321. J Clin Pharmacol. 2004. PMID: 15342618

7

Characterization of mutator phenotype in familial colorectal cancer patients not fulfilling amsterdam criteria.

Kim JC, Lee KH, Ka IH, Koo KH, Roh SA, Kim HC, Yu CS, Kim TW, Chang HM, Gong GY, Kim JS. Kim JC, et al. Among authors: chang hm. Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6159-68. doi: 10.1158/1078-0432.CCR-04-0651. Clin Cancer Res. 2004. PMID: 15448003

8

Phase II study of paclitaxel and carboplatin in advanced gastric cancer previously treated with 5-fluorouracil and platinum.

Chang HM, Kim TW, Ryu BY, Choi SJ, Park YH, Lee JS, Kim WK, Kang YK. Chang HM, et al. Jpn J Clin Oncol. 2005 May;35(5):251-5. doi: 10.1093/jjco/hyi077. Epub 2005 May 10. Jpn J Clin Oncol. 2005. PMID: 15886269 Clinical Trial.

9

Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer.

Kim JC, Kim TW, Kim JH, Yu CS, Kim HC, Chang HM, Ryu MH, Park JH, Ahn SD, Lee SW, Shin SS, Kim JS, Choi EK. Kim JC, et al. Among authors: chang hm. Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):346-53. doi: 10.1016/j.ijrobp.2005.02.046. Int J Radiat Oncol Biol Phys. 2005. PMID: 15913913 Clinical Trial.

10

Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate.

Ryu MH, Lee JL, Chang HM, Kim TW, Kang HJ, Sohn HJ, Lee JS, Kang YK. Ryu MH, et al. Among authors: chang hm. Jpn J Clin Oncol. 2006 Jan;36(1):17-24. doi: 10.1093/jjco/hyi212. Epub 2006 Jan 17. Jpn J Clin Oncol. 2006. PMID: 16418188

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

872 results

Search Page

Filters